Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Queensland Health
Chubb
Deloitte
Healthtrust
AstraZeneca
QuintilesIMS
Merck
US Department of Justice
Cerilliant

Generated: October 20, 2017

DrugPatentWatch Database Preview

Apotex Company Profile

« Back to Dashboard

What is the competitive landscape for APOTEX, and what generic alternatives to APOTEX drugs are available?

APOTEX has two hundred and ninety-three approved drugs.

There are five US patents protecting APOTEX drugs on APOTEX drugs in the past three years. There are seventeen tentative approvals on APOTEX drugs.

There are two hundred and fourteen patent family members on APOTEX drugs in fifty-one countries and three hundred and ten supplementary protection certificates in thirteen countries.

Summary for Applicant: Apotex

International Patents:214
US Patents:5
Tradenames:219
Ingredients:207
NDAs:293
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apotex Inc
LEVOFLOXACIN
levofloxacin
TABLET;ORAL090787-001Sep 29, 2011ABRXNoNo► Subscribe► Subscribe► Subscribe
Apotex Inc
PRAVASTATIN SODIUM
pravastatin sodium
TABLET;ORAL076341-002Oct 23, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe
Apotex Inc
GABAPENTIN
gabapentin
TABLET;ORAL077894-001Oct 10, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe
Apotex Inc
OLANZAPINE
olanzapine
TABLET;ORAL090798-006Apr 23, 2012ABRXNoNo► Subscribe► Subscribe► Subscribe
Apotex
GLIPIZIDE
glipizide
TABLET;ORAL075795-002Jun 13, 2001ABRXNoNo► Subscribe► Subscribe► Subscribe
Apotex Inc
TORSEMIDE
torsemide
TABLET;ORAL076894-002May 31, 2005ABRXNoNo► Subscribe► Subscribe► Subscribe
Apotex
KETOCONAZOLE
ketoconazole
TABLET;ORAL075912-001Jan 10, 2002DISCNNoNo► Subscribe► Subscribe► Subscribe
Apotex
ALENDRONATE SODIUM
alendronate sodium
TABLET;ORAL077982-002Aug 4, 2008ABRXNoNo► Subscribe► Subscribe► Subscribe
Apotex Inc
MOEXIPRIL HYDROCHLORIDE
moexipril hydrochloride
TABLET;ORAL078454-002Jun 2, 2008ABRXNoNo► Subscribe► Subscribe► Subscribe
Apotex Inc
BENAZEPRIL HYDROCHLORIDE
benazepril hydrochloride
TABLET;ORAL077128-004Mar 8, 2006ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Apotex

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apotex Technologies
PAXIL
paroxetine hydrochloride
CAPSULE;ORAL020885-001Oct 9, 1998► Subscribe► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
CAPSULE;ORAL020885-004Oct 9, 1998► Subscribe► Subscribe
Apotex Technologies
PAXIL CR
paroxetine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020936-001Feb 16, 1999► Subscribe► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
CAPSULE;ORAL020885-003Oct 9, 1998► Subscribe► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
TABLET;ORAL020031-003Dec 29, 1992► Subscribe► Subscribe
Apotex Technologies
PAXIL CR
paroxetine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020936-001Feb 16, 1999► Subscribe► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
SUSPENSION;ORAL020710-001Jun 25, 1997► Subscribe► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
CAPSULE;ORAL020885-002Oct 9, 1998► Subscribe► Subscribe
Apotex Technologies
PAXIL CR
paroxetine hydrochloride
TABLET, EXTENDED RELEASE;ORAL020936-002Feb 16, 1999► Subscribe► Subscribe
Apotex Technologies
PAXIL
paroxetine hydrochloride
TABLET;ORAL020031-003Dec 29, 1992► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for APOTEX drugs

Drugname Dosage Strength Tradename Submissiondate
omeprazole
Delayed-release Tablets20 mg
OMEPRAZOLE
6/3/2015
paroxetine hydrochloride
Extended-release Tablets37.5 mg
PAXIL CR
5/19/2009
paroxetine hydrochloride
Extended-release Tablets25 mg
PAXIL CR
9/9/2005
paroxetine hydrochloride
Oral Suspension10 mg/5 mL
PAXIL
2/10/2005

International Patent Family for Apotex Drugs

Country Document Number Estimated Expiration
Denmark1020464► Subscribe
Norway20006547► Subscribe
Portugal839039► Subscribe
Cyprus2408► Subscribe
South Africa9902899► Subscribe
Brazil9609857► Subscribe
Denmark199901730► Subscribe
Hungary0103712► Subscribe
Spain2159260► Subscribe
Algeria2074► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Apotex Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0722Netherlands► SubscribePRODUCT NAME: TOBRAMYCINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: C(2011)5394 20110720
70044Netherlands► SubscribePRODUCT NAME: CANDESARTAN, DESGENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF VAN DE 1-(CYCLOHEXYLOXYCARBONYLOXY) ETHYLESTE R, IN HET BIJZONDER CILEXETILI CANDESARTANAS, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: RVG 21703 - RVG 21706 19971013; FIRST REGISTRATION: GB PL 15661/0001 - PL 15661/0004 19970429
90027-0Sweden► SubscribePRODUCT NAME: TRAVOPROST
2008013Lithuania► SubscribePRODUCT NAME: SITAGLIPTINUM PHOSPHAS MONOHYDRICUS, METFORMINI HYDROCHLORIDUM; REG. NO/DATE: EU/1/08/455/001-014 20080716
/1999Austria► SubscribePRODUCT NAME: NEVIRAPINE; REGISTRATION NO/DATE: EU/1/97/055/001 19980205
C/GB03/018United Kingdom► SubscribePRODUCT NAME: DUTASTERIDE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SOLVATE.; REGISTERED: SE 17871 20020719; SE 17872 20020719; UK PL 19494/0005 20030117; UK PL 19494/0006 20030117
00567Netherlands► SubscribePRODUCT NAME: DASATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/06/363/001 .... 009 20061120
C/GB97/089United Kingdom► SubscribePRODUCT NAME: ZOLMITRIPTAN AND OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK 12619/0116 19970307
C0055France► SubscribePRODUCT NAME: ANASTROZOLE, EVENTUELLEMENT SOUS LA FORME D’UN SEL D’ADDITION ACCEPTABLE EN MEDECINE PHARMACEUTIQUE; REGISTRATION NO/DATE IN FRANCE: NL 21126 DU 19961227; REGISTRATION NO/DATE AT EEC: 12619/0106 DU 19950811
C/GB12/058United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Covington
Fuji
Cerilliant
AstraZeneca
Chinese Patent Office
Moodys
Johnson and Johnson
Fish and Richardson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot